LRIG1 and breast cancer: We next went on to test the combination of Panobinostat and ADC, finding this was not consistently superior to ADC alone (except in HCC1937 cells); suggesting that methylation, not deacetylation, is the dominant epigenetic mechanism of LRIG1 silencing in breast cancer.